Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03344887
Other study ID # 20170477-01H
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date September 4, 2018
Est. completion date December 1, 2022

Study information

Verified date June 2022
Source Ottawa Hospital Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The iTADS trial will test an important blood donor characteristic - donor sex - to see whether male donor blood leads to a greater benefit for transfusion recipients compared to female donor blood. The trial will help determine how the investigators can tailor the selection of blood donors based on donor characteristics (e.g. sex) to further improve the safety and optimize the clinical benefit of blood products in Canada.


Description:

The investigators have designed an innovative pragmatic randomized trial that will allocate transfusion recipients to receive either only male or only female donor transfusions. Primary objective: To confirm that a transfusion strategy of receiving male donor RBC (Red Blood Cell) units only will improve survival compared to a transfusion strategy of female donor RBC units in all hospital patients requiring a transfusion. Secondary objectives: 1. To assess effects of male RBC units on major morbidities (cancer, infection, end-organ damage) 2. To assess effects across major patient subgroups (major surgery, intensive care, oncology) 3. To assess the effect of female donor pregnancy history on recipient transfusion outcome 4. To build capacity to conduct large innovative prospective pragmatic clinical trials in transfusion medicine using routinely collected clinical and administrative information.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 8850
Est. completion date December 1, 2022
Est. primary completion date January 23, 2021
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - All patients (excluding neonates) requiring one or more allogeneic RBC transfusions for the treatment of anemia will be included. Exclusion Criteria: - Patients that do not have a valid Ontario Health Insurance Plan (OHIP) number at time of first transfusion - Patients that require emergent release of a RBC transfusion and in whom emergency randomization could not be completed - Patients with complex antibody profile in which it is impossible to match RBC units

Study Design


Related Conditions & MeSH terms


Intervention

Other:
RBC Transfusion from male donor
Patients requiring an RBC transfusion for the treatment of anemia will receive products from a male donor at initial and any subsequent hospitalizations during the trial period.
RBC Transfusion from female donor
Patients requiring an RBC transfusion for the treatment of anemia will receive products from a female donor at initial and any subsequent hospitalizations during the trial period.

Locations

Country Name City State
Canada Ottawa Hospital - General Campus Ottawa Ontario

Sponsors (3)

Lead Sponsor Collaborator
Ottawa Hospital Research Institute Canadian Blood Services, Canadian Institutes of Health Research (CIHR)

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Survival Measured from date of first randomization to date of death or end of study 2 years from first patient enrollment. 2 years
Secondary Survival Measured from date of first randomization to date of death or end of study 2 years from the first patient enrollment. 30 days, 3 months, 6 months and 1 year
Secondary Length of hospital stay Number of days admitted to hospital for the treatment of anemia. 2 years
Secondary New ICU admission Occurrence of ICU admission(s) once discharged for the treatment of anemia. 2 years
Secondary Re-hospitalization Occurrence of additional hospital admission(s) once discharged for the treatment of anemia. 2 years
Secondary Health system costs The cost of the treatment of anemia and any related downstream health care resources. 2 years
Secondary Occurrence of new cancer The number of new cancer diagnoses, not present during the initial treatment of anemia. 2 years
Secondary Recurrence of cancer The number of repeat cancer diagnoses, diagnosed previous to the initial treatment of anemia. 2 years
Secondary Infection rates Methicillin-resistant Staphylococcus aureus and Clostridium difficile for hospital-acquired infections. 2 years
Secondary New occurrence of hemodialysis For severe chronic renal failure. 2 years
Secondary Myocardial infarctions For cardiac events. 2 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06230198 - The Effect of Retrograde Autologous Priming on Transfusion Requirements After Cardiac Surgery N/A
Recruiting NCT04757909 - Detection of Anemizations in Primary Care. N/A
Terminated NCT02566577 - Physiologic Effects of RBC Transfusion Phase 4
Recruiting NCT04920045 - A Trial to Assess the Effect of Transfusion Strategies on Fatigability Levels After Hospital Discharge N/A
Completed NCT01258010 - Impact of Tranexamic Acid on Red Blood Cell Transfusion in Spinal Surgery N/A
Recruiting NCT05405426 - Trial of Indication-Based Transfusion of Red Blood Cells in ECMO N/A
Completed NCT05798130 - Assessment of Oxygen Extraction Rate Changes Following Red Blood Cell Transfusion in the Intensive Care Unit